Prostate Cancer

Toxicity complications were assessed between single- and multiple-treatment modalities for patients with localized prostate cancer.

Panelists discuss how PSMA PET imaging identified a region of high tracer uptake, guiding medical professionals to implement a focal radiation boost. This approach improved treatment precision and targeting of aggressive areas, highlighting the potential for personalized, effective therapies.

Panelists discuss how PSMA PET imaging has significantly influenced prostate cancer management by enabling precise detection of metastatic lesions, thereby informing and altering treatment strategies. For instance, a study demonstrated that ^68Ga-PSMA-11 PET/CT impacted definitive radiation therapy (RT) planning in 16.5% of patients, leading to modifications in RT fields based on the imaging findings.

Administering 177Lu for mCRPC is a “team sport”, according to Steven Finkelstein, MD, DABR, FACRO.

Panelists discuss how PSMA PET imaging is increasingly utilized to assess treatment response in prostate cancer, offering superior accuracy over PSA monitoring alone. Incorporating PSMA PET into clinical practice involves considering factors such as timing post treatment and the specific clinical scenario. For instance, studies have demonstrated that PSMA PET/CT can detect intraprostatic and metastatic lesions even at very low PSA levels during treatment monitoring.

Panelists discuss how, PSMA PET imaging significantly enhances surgical decision-making in prostate cancer by precisely identifying tumor location, extent, and metastatic spread with superior sensitivity compared to conventional imaging. This molecular targeting enables more accurate surgical planning, improved patient selection for radical prostatectomy versus targeted approaches, and better identification of lymph node involvement, ultimately allowing for personalized treatment strategies that maximize oncological outcomes while minimizing unnecessary interventions.

After the recent approval of 177Lu in PSMA+/mCPRCP prior to chemotherapy, Steven Finkelstein, MD, DABR, FACRO, highlights the importance of this milestone.

Steven Finkelstein, MD, DABR, FACRO, spoke about the impact of the approval of 177Lu for patients with PSMA-positive mCRPC.

Results from the KEYNOTE-921 trial demonstrated that pembrolizumab with docetaxel did not elicit efficacy improvements vs placebo with docetaxel in prostate cancer.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.

Daniel Kim, MD, MBA discusses how genomic testing has revolutionized patient selection for active surveillance by integrating molecular insights that transcend traditional clinical parameters, enabling more nuanced risk stratification and personalized management of intermediate-risk prostate cancer.

Dwight E. Heron, MD, MBA, FACRO, FACR discusses how advanced multi-omics approaches, personalized precision medicine techniques, artificial intelligence–driven genetic interpretation tools, and emerging gene editing technologies such as CRISPR (clustered regularly interspaced short palindromic repeats) are poised to revolutionize clinical practice by enabling more targeted diagnostics, predictive risk assessments, and individualized treatment strategies across oncology, rare disease management, and chronic condition prevention.

Christopher Lee, MD discusses how genomic biomarker testing has revolutionized prostate cancer management by enabling a precision medicine approach that transitions from population-based treatments to individualized therapeutic strategies based on precise molecular profiling.

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

A cohort study found that pre-radical prostatectomy levels greater than 20 ng/mL were associated with increased all-cause mortality risk and prostate cancer-specific mortality risk.

The adverse effect profile was similar among patients with prostate cancer using NeuroSAFE-assisted RARP vs standard RARP.

The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Prior data support the ability of PATHOMIQ_PRAD to predict patients at a high risk of biochemical recurrence and metastasis.

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.

Data show improvements in overall survival and time to subsequent therapy initiation with darolutamide plus ADT/docetaxel.

Olaparib plus abiraterone improved radiographic PFS and overall survival in mCRPC patients with germline or somatic BRCA mutations vs placebo plus abiraterone.

The hood technique, developed by Ash Tewari, MD, aids in facilitating earlier returns of continence with reduced residual cancer rates.